Efficacy and safety of transcatheter arterial chemoembolization combined with systemic chemotherapy in urothelial carcinoma patients with liver metastasis / 肿瘤

ABSTRACT

Objective: To investigate the efficacious and safe therapy for urothelial carcinoma patients with liver metastasis. Methods: A total of 42 urothelial carcinoma patients with liver metastasis from December 2006 to December 2016 at Department of Renal Carcinoma and Melanoma in Beijing Cancer Hospital were included in this retrospective study. All patients were divided into three groups, and treated with paclitaxel plus gemcitabine, paclitaxel plus gemcitabine and cisplatin, or paclitaxel plus gemcitabine combined with transcatheter arterial chemoembolization (TACE), respectively. The treatment continued until disease progression or intolerable adverse reactions occurred. The efficacy and treatment-related adverse reactions in different groups were analyzed specifically. Results: For the 42 patients, the median progression-free survival time (PFS) was 2.0±0.7 months [95% confidence interval (CI) 0.6-3.4], and the median overall survival time (OS) was 6.1±1.7 months (95% CI 4.1-9.9). For the 12 patients receiving TACE combined with systemic chemotherapy, the median PFS was 7.1 ±0.7 months (95% CI 5.7-8.5), the median OS was 14.1 ±3.0 months (95% CI 8.3-19.9), which were statistically different from those in systemic chemotherapy group (both P < 0.01). The patients could tolerate TACE combined with systemic chemotherapy. The common adverse effects were gastrointestinal reaction at grade 1-2, upper abdominal pain and leukopenia. Conclusion: TACE combined with systemic chemotherapy is an efficacious and safe treatment regimen for urothelial carcinoma patients with liver metastasis.